|
|
||||||||
Eur J Cardiothorac Surg 2001;19:840-847
© 2001 Elsevier Science NL
a Department of Cardiac Surgery, Ludwig-Maximilians University, Munich, Germany
b Department of Cardiology, Ludwig-Maximilians University, Munich, Germany
c Department of Surgical Research, Ludwig-Maximilians University, Munich, Germany
Received 9 October 2000; received in revised form 28 February 2001; accepted 13 March 2001.
Corresponding author. Tel.: +49-89-7095-6464; fax: +49-89-7095-8873
e-mail: wildhirt{at}hch.med.uni-muenchen.de
| Abstract |
|---|
|
|
|---|
were measured in plasma samples from the aorta and coronary sinus. Results: CFVR was impaired in 26.1% (n=11) of patients at 1 month and in 31% (n=13) 12 months after HTx. iNOS-mRNA levels were significantly higher in patients with impaired endothelium-dependent CFVR. In addition, only in these patients were TNF-
levels higher and these correlated with plasma NOx levels at 1 and 12 months post-HTx (1 month: r=0.81, P=0.001; 12 months: r=0.62, P=0.04). Conclusions: Coronary microcirculatory dysfunction in response to acetylcholine is present in nearly 30% of patients during the first year following transplantation. These patients present with higher iNOS-mRNA expression and TNF-
plasma levels. Selective modulation of the TNF-
/iNOS-pathway may be of therapeutic value to improve coronary endothelial dysfunction in cardiac transplant recipients.
Key Words: Heart transplantation Endothelial function Inducible nitric oxide synthase Cytokines Humans
| 1. Introduction |
|---|
|
|
|---|
Based on these observations, we determined the relationship between coronary vasomotor function in epicardial and microvascular compartments in response to endothelium-dependent and -independent stimuli and the expression of iNOS and endothelial constitutive nitric oxide synthase (ecNOS) in simultaneously procured endomyocardial biopsies. In addition, the production/release of total NOx and TNF-
was measured in aortic and coronary sinus (CS) blood samples.
| 2. Methods |
|---|
|
|
|---|
|
Left heart catheterization was performed at 1 and 12 months after HTx and consisted of a measurement of hemodynamics and routine coronary angiography to exclude donor transmitted coronary artery disease. In addition, an assessment of endothelium-dependent and -independent epicardial (quantitative coronary angiography) and microvascular (Doppler flow-wire) coronary vasomotor function was performed.
At each follow-up appointment, endomyocardial biopsies were obtained from the interventricular septum for determination of iNOS- and ecNOS-messenger RNA (mRNA) expression. To account for differences in sample quality, we always used homogenates from two biopsy samples for each reverse-transcriptase polymerase chain reaction (RT-PCR) analysis. Blood samples from the aorta and CS were withdrawn for measurement of TNF-
(pg/ml) and total NOx (nitrate/nitrite; µM).
2.2. Functional assessment of coronary vasomotor function
2.2.1. Endothelium-dependent and -independent epicardial vasomotion
Quantitative coronary angiography with a computerized automatic-analysis system (Hicor, Siemens) was used to assess the coronary vasomotor response (epicardial luminal diameter changes (%)) to the following stimuli: endothelium-dependent with intracoronary administration of acetylcholine (Ach; 1.0 and 30.0 µg/min for 5 min each) and endothelium-independent with intracoronary infusion of adenosine (80.0 and 160.0 µg/min for 5 min each) as described elsewhere. No pathological vasoconstriction was observed during the investigation. Since autoregulation maintains constant coronary flow over a range of perfusion pressures, changes observed in the microvasculature were not due to epicardial vasoconstriction [10].
2.2.2. Endothelium-dependent and -independent microvascular vasomotion
Microvascular vasomotor response was assessed by flow velocity measurements with an intracoronary Doppler flow-wire (0.018 inch (0.04 cm); Flo Wire, Cardiometrics, Inc., USA). The flow-wire was introduced in a 6 F Judkins catheter and positioned in the proximal part of the left anterior descending or circumflex coronary artery. After baseline flow velocity readings were obtained, hyperemic flow velocity data were determined with intracoronary adenosine infusion (Ad; 80.0 and 160.0 µg/min over 5 min each). Endothelium-dependent changes in flow velocity were measured with intracoronary infusion of acetylcholine (Ach; 1.0 and 30.0 µg/min over 5 min each). The coronary flow velocity reserve (CFVR) was expressed as the ratio of peak to baseline blood flow velocity. Heart rate, mean arterial pressure, coronary flow velocity and electrocardiogram were monitored continuously throughout the procedure. It was assured that measurements of the flow velocity reserve of the microvascular bed were not altered by epicardial vasoconstriction during acetylcholine infusion. An increase in the flow velocity below factor 2.0 was considered pathological [11].
2.3. Intravascular ultrasound
Immediately after Doppler flow measurement, intracoronary ultrasound (ICUS) was performed to detect intimal hyperplasia not detectable by angiography at 1 month post-transplant. Before intravascular positioning, 200 µg of nitroglycerin was injected into the left coronary artery. The imaging system consisted of a 30-MHz ultrasound transducer enclosed within an acoustic housing on the tip of a 2.9 F flexible, rapid-exchange catheter (CVIS, Inc., Sunnyvale, CA, USA). The catheter was advanced to the distal left anterior descending or circumflex artery, with careful observance of the lumenICUS catheter diameter ratio of >1.5. During the subsequent standardized pullback maneuver, images were documented on SVHS videotape for further off-line analysis. The three sites with the most severe intimal proliferation were evaluated semiquantitatively concerning the radial and circumferential extent of intimal hyperplasia, and the averaged maximal intimal thickness was calculated. The mean maximal intimal thickening (MIT) was determined using a minimum of five randomized proximal to distal sites. The data are expressed as: 1, normal vessel morphology; 2, mild MIT (<300 µg); 3, moderate MIT (300600 µg); 4, severe MIT (>600 µg). The predominant MIT localization is separated in three types: (a), proximal; (b), distal; (c), diffuse localization.
2.4. Detection of iNOS- and ecNOS-mRNA by RT-PCR
Endomyocardial biopsy samples were immediately frozen in liquid nitrogen and stored at -80°C. For RNA extraction and cDNA preparation, the technique described previously was used.
An aliquot (3 µl) of cDNA was amplified by PCR with a DNA thermal cycler (PerkinElmer 480, Cetus Corp., Norwalk, CT). The amplification reaction was carried out as described. The nucleotide sequences of the chosen primers were as follows: glycerolaldehyde-3-phosphate dehydrogenase (GAPDH), 5'-TGAAGGTCGGAGTCAACGGATTTGGT-3' for sense and 5'-CATGTGGGCCATGAGGTCCACCAC-3' for antisense (product size, 983 bp); iNOS, 5'-GGCCTGGAAACGCACAAGCTG-3' for sense and 5'-TTGGGGTTGAAGGCACAGCTG-3' for antisense (product size, 506 bp); ecNOS, 5'-GAAGAGGAAGGAGTCCAGTAACAC-3' for sense and 5'-GGTGGCCCTCGTGGACTTGCTG-3' for antisense (product size, 451 bp). Semiquantitative analysis was performed using a densitometric analysis system. It was assured that the amplification was within the linear range of the particular primer studied. Each signal was normalized for the DNA standard of the same gel to account for variances between gels. Normalization for the housekeeping gene, GAPDH, was performed to account for the variability in sample quality.
2.5. Measurement of plasma NOx and TNF-
Total NOx levels were measured by the Griess reaction as described previously [12]. In brief, plasma was deproteinized by ultrafiltration (Centrifree micropartition system, Amicon, Beverly, MA). The nitrate content of the sample was reduced to nitrite with a nitrate reductase. Samples were measured by spectrophotometric analysis at 540 nm. A standard curve was performed in each experiment. The NOx content of the samples was calculated from the standard curve, which was linear within this range.
TNF-
was measured by a commercially available, enzyme-linked immunoabsorbant assay (ELISA, Medgenix, Ratingen, Germany). All samples were run in duplicate and the optical density was read at the appropriate wavelength.
2.6. Data analysis
The CFVR to acetylcholine was considered normal when the flow increase was above factor 2.0 from the baseline level. Nominal data were analyzed with Fisher's Exact test. Normally distributed data were analyzed with either the paired or unpaired Student's t-test as appropriate, and correlations were determined with single regression analysis. Multiple comparisons were performed with ANOVA and corrected with Bonferroni-post-hoc analysis. Non-normally distributed data were analyzed using the MannWhitney U-test. The data are expressed as means±SD. P values of <0.05 were considered statistically significant. For multiple comparisons, a P value of <0.002 was considered statistically significant.
| 3. Results |
|---|
|
|
|---|
None of the patients included in the investigation had clinical signs of infection or acute rejection episodes of ISHLT grade 1b or greater during the time of sample collection and functional assessment of the coronary vasculature. Moreover, no significant differences with regard to the number of acute cellular rejection episodes were found between the two groups (Table 1).
The patients did not differ with regard to the number of classic atherosclerotic risk factors, such as hypertension, hyperlipidemia, diabetes or history of smoking.
In addition, no significant differences with regard to cardiac hemodynamics were observed at both follow-up appointments. Moreover, we found no correlation between NOS-gene expression or NOx levels and cardiac hemodynamics at any time point (data not shown).
3.2. Epicardial vasomotor function
The administration of acetylcholine resulted in epicardial coronary diameter changes of -5±2% in proximal and -11±5% in distal segments at 1 month, and -7±3% in proximal and -12±4% in distal segments 12 months after HTx.
The administration of adenosine resulted in epicardial vasodilator changes of 7±3% in proximal segments and 17±6% in distal segments at 1 month, and 6±2% in proximal and 15±8% in distal segments 12 months after transplantation. Epicardial vasomotor responsiveness to both acetylcholine and adenosine was not associated with endomyocardial expression of both iNOS and ecNOS-mRNA.
3.3. Microvascular vasomotor function
Eleven out of 42 patients (26.1%) showed an impaired CFVR in response to acetylcholine 1 month after HTx which was significantly different from those patients with a normal increase in CFVR (Fig. 1). At 1 year post-transplant, 13 patients (31%) presented with an impaired CFVR. These patients also showed a significantly reduced endothelium-independent microvascular vasomotor function in response to adenosine 12 months after HTx (Fig. 1).
|
Vice versa, nine out of 13 patients (69.2%) with an impaired CFVR in response to acetylcholine at 12 months following HTx demonstrated a normal CFVR at 1 month after HTx.
3.4. Coronary morphological alterations
At 1 month following HTx, no differences concerning the extent of coronary intimal thickening were observed between patients with impaired and normal endothelium-dependent CFVR (Table 2).
|
|
3.6. Plasma TNF-
and NOx levels
The overall TNF-
levels (pg/ml) remained elevated throughout the first year following HTx (1 month, 19.5±2.3; 6 months, 21.5±4.8; 12 months, 23.6±±4.5; P=0.02 for 1 vs. 12 months). Patients with impaired CFVR had significantly higher plasma levels of TNF-
at 1 and 12 months after HTx (Fig. 3A).
|
levels only in patients with an impaired CFVR to acetylcholine at both 1 and 12 months following HTx (Fig. 3C,D). No correlation was found in patients with normal CFVR in response to acetylcholine at either time point (1 month: r=0.22, P=0.28; 12 months: r=0.19, P=0.67). | 4. Discussion |
|---|
|
|
|---|
production at 1 and 12 months following HTx and occurs in the absence of macroscopic lesions of the coronary arteries, as well as acute infection and rejection episodes.
The data demonstrate that under immunosuppressive therapy sufficient to prevent acute rejection episodes, a considerable inflammatory process is active within the allograft. This inflammatory process may not be limited to an early phase (1 month post-HTx), but is persistent as shown by the 6 and 12 month levels for TNF-
and iNOS-mRNA. iNOS-gene expression may be involved in the functional alteration of the microvascular endothelium since, in these patients, its expression was significantly higher at 1 and 12 months post-HTx. It demonstrates, in the clinical setting, that the persistent up-regulation of inflammatory mediators contributes to endothelial dysfunction. It is of importance to note that there was no correlation between NOS-gene expression or NOx levels and cardiac hemodynamics at any time point. This is in line with data from Birks et al., who studied prospectively the potential role of nitric oxide (as measured by plasma nitrates) on myocardial function following human HTx [13].
It is known that plasma NOx varies between individuals and may depend on food intake, renal function and medication. We believe that in this clinical study, an association between the two parameters, plasma NOx and TNF-
, more accurately reflects a certain pathophysiological condition than one alone (i.e. plasma NOx). The subgroup analysis on plasma NOx levels between patients with and without impaired CFVR did not reveal significant differences. However, the interaction between NOx and TNF-
in the subgroup of patients with impaired microvascular function at 1 and 12 months suggests that the inflammatory system is activated.
In this regard, experimental studies with iNOS-deficient mice suggest that the development of TxCAD is augmented in the absence of iNOS [14]. In addition, it has been demonstrated by Shears and colleagues that transfection of the iNOS-gene protects against the development of TxCAD by inhibition of intimal and medial thickening [15].
In contrast, Akyürek and colleagues found iNOS expression in infiltrating cells and vascular smooth muscle cells in neointima and media during the development of experimental transplant arteriosclerosis in rats [16]. Skarsgard and colleagues demonstrated direct vasodilation and inhibition of the myogenic tone of vascular smooth muscle cells by both ecNOS and iNOS-based NO-production in allograft resistance vessels [17]. Indeed, as shown in Fig. 1, patients with an impaired CFVR and high iNOS-mRNA levels also developed endothelium-independent vasomotor function in response to adenosine, suggesting an alteration of vasomotor function downstream to the coronary endothelium. Since acetylcholine-mediated vasodilation in the coronary circulation is, in part, mediated by NO, the functional alteration of this pathway may be involved. In addition, supporting evidence that iNOS is involved in the development of TxCAD in humans has been reported by Ravalli and colleagues. They studied tissue from 15 patients with TxCAD and compared their findings with ten patients having normal coronary arteries. They found a significantly higher expression of both iNOS and nitrotyrosine in the TxCAD group. iNOS was expressed in macrophages and smooth muscle cells and was co-localized with nitrotyrosine formation, suggesting that iNOS, and possibly, peroxynitrite, contribute to the progression of TxCAD in humans [18].
What are the underlying mechanisms for iNOS-mediated endothelial dysfunction of the coronary microcirculation before morphological changes occur?
One possibility is that higher (iNOS-derived) NO concentrations (or its cytotoxic reaction product, peroxynitrite) trigger cellular activation, possibly by NO-dependent formation of secondary oxidants such as peroxynitrite [19,20]. It has been shown that the extent of apoptotic cell death by cytokine-induced NO production is modulated by the availability of oxygen free radicals and by alterations in the cellular balance of Bak and Bcl-xL [21].
Other factors may be synergetic with an enhanced iNOS expression contributing to endothelial dysfunction. Bauersachs and colleagues demonstrated that increased superoxide production by a NADH-dependent oxidase plays an important role in the development of endothelial dysfunction in chronic myocardial infarction [22]. This may occur by increased formation of peroxynitrite (in the presence of high NO levels) and reduced NO-bioactivity due to its inactivation by superoxide [23,24]. In this regard, it has been shown that peroxynitrite inactivates manganese superoxide dismutase, thereby promoting irreversible oxidative injury in chronic rejection of human renal allografts [25].
In conclusion, the present study demonstrates for the first time that in human cardiac transplant recipients, endothelial dysfunction of the coronary microcirculation parallels an enhanced endomyocardial iNOS-mRNA expression which may be regulated by the proinflammatory cytokine, TNF-
. Selective modulation of the TNF-
/iNOS-pathway may be a novel therapeutic target in cardiac transplant recipients and may help to prevent the transition from endothelial dysfunction to coronary morphological changes.
| Acknowledgments |
|---|
| Footnotes |
|---|
| Appendix A. Conference discussion |
|---|
|
|
|---|
Dr Wildhirt: We would suggest to test the potential benefit of selective iNOS inhibitors with regard to the development of transplant atherosclerosis in both experimental and clinical studies. This follows experimental studies, one recently published in Circulation by Behr-Rousse and colleagues from the group in Paris showing that the chronic treatment with a highly-selective iNOS inhibitor, and it was L-NIL in this case, and actually prevented the development of morphological changes in the native atherosclerosis model using hypercholesterolemic rabbits. We currently study, in a rat model of heterotopic allograft transplantation, selective iNOS inhibitors of various forms, and there will be more and more specific selective inhibitors in the future, and simultaneous inhibition of superoxide production on a longitudinal basis to see whether or not we can prevent the development of transplant atherosclerosis. Of course, it would be interesting clinically to add those inhibitors to the preservation solutions and finally treat those patients on a long-term basis.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. C. Stoica, D. K. Satchithananda, C. Atkinson, S. Charman, M. Goddard, and S. R. Large Heat shock protein, inducible nitric oxide synthase and apoptotic markers in the acute phase of human cardiac transplantation Eur. J. Cardiothorac. Surg., December 1, 2003; 24(6): 932 - 939. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |